Archive for the 'Lymphoma / Leukemia' Category
Seaweed Extract May Hold Promise For Non-Hodgkin’s Lymphoma Treatment
Seaweed extract may eventually emerge as a lymphoma treatment, according to laboratory research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held here March 7-10, 2010…Original post by Diabetes Daily
No commentsInfectious Virus Hidden In Chromosomes During Latency Can Be Passed From Parents To Children
Human herpesvirus 6 (HHV-6) infects nearly 100 percent of humans in early childhood, and the infection then lasts for the rest of a person’s life…Original post by Six Until Me.
No commentsKey Cause Of Chronic Leukemia Progression Identified By Study
Researchers have discovered a key reason why a form of leukemia progresses from its more-treatable chronic phase to a life-threatening phase called blast crisis. The study, led by cancer researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J…Original post by Diabetes Mine
No commentsNICE Set To Recommend Rituximab For Relapsed Or Refractory Chronic Lymphocytic Leukaemia
The National Institute for Health and Clinical Excellence (NICE) has today (4 March) issued final draft guidance recommending the drug rituximab(MabThera) as a treatment for certain patients with relapsed or refractory chronic lymphocytic leukaemia…Original post by Dental Heroes
No commentsNICE Appraisal Of Azacitidine For Myelodysplastic Syndromes
The National Institute for Health and Clinical Excellence (NICE) is currently appraising the use of azacitidine (Vidaza, Celgene) for myelodysplastic syndromes…Original post by Dental Heroes
No commentsTargeting Leukaemia Cell’s Gene ‘addiction’ Presents New Strategy For Treatment
An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become ‘addicted’ to genes, which if targeted could prevent diseased cells from developing…Original post by Diabetes Daily
No commentsFDA Sets March 22 For ODAC Meeting To Review CTI’s New Drug Application For Pixantrone
Cell Therapeutics, Inc. (”CTI”) (Nasdaq and MTA: CTIC) announced that the U.S. Food and Drug Administration’s (”FDA”) Oncologic Drugs Advisory Committee (”ODAC”) will review CTI’s New Drug Application (”NDA”) for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin’s lymphoma (”NHL”) on March 22, 2010…Original post by Diabetes Daily
No commentsOver-Expression Of Gene Regulator Spurs Development Of Leukemia In Babies With Down Syndrome
Between 5 and 10 percent of babies with Down syndrome develop a transient form of leukemia that usually resolves on its own. However, for reasons that haven’t been clear, 20 to 30 percent of these babies progress to a more serious leukemia known as Down syndrome acute megakaryoblastic leukemia (DS-AMKL), which affects the blood progenitor cells that form red blood cells and platelets…Original post by Dr John Biffa’s Blog
No commentsOvercoming Multidrug Resistance In Acute Lymphoblastic Leukemia Cells
Acute lymphoblastic leukemia (ALL) most commonly affects children, in whom there is an overall cure rate of 85%. A strong predictor of poor outcome is resistance to chemotherapy with glucocorticoids. Such resistance is caused, at least in part, by an inability of the leukemic cells to die by a process known as mitochondrial apoptosis…Original post by Dr John Biffa’s Blog
No commentsChildren And Teens Less Likely Than Young Adults To Die Of Non-Hodgkin’s Lymphoma
Young adults diagnosed with non-Hodgkin’s lymphoma appear to have a higher risk of dying from the disease than do children and teens. Eric Tai, M.D…Original post by Diabetes Mine
No comments